Altimmune Inc
General ticker "ALT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $623.6M
Altimmune Inc does not follow the US Stock Market performance with the rate: -12.7%.
Estimated limits based on current volatility of 3.8%: low 7.78$, high 8.40$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [5.70$, 14.67$]
- 2024-12-30 to 2025-12-30 estimated range: [4.32$, 11.50$]
Financial Metrics affecting the ALT estimates:
- Negative: Non-GAAP EPS, $ of -1.65 <= 0.10
- Negative: Operating profit margin, % of -99.56 <= 1.03
- Negative: Operating cash flow per share per price, % of -18.62 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term ALT quotes
Long-term ALT plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $4.41MM | $0.00MM | $0.43MM |
Operating Expenses | $101.32MM | $87.74MM | $96.36MM |
Operating Income | $-96.91MM | $-87.74MM | $-95.93MM |
Non-Operating Income | $-0.18MM | $2.83MM | $7.48MM |
Interest Expense | $0.01MM | $0.01MM | $0.04MM |
R&D Expense | $74.54MM | $70.54MM | $65.80MM |
Income(Loss) | $-97.09MM | $-84.91MM | $-88.45MM |
Taxes | $0.00MM | $-0.20MM | $0.00MM |
Profit(Loss) | $-97.09MM | $-84.71MM | $-88.45MM |
Stockholders Equity | $199.13MM | $185.29MM | $194.10MM |
Assets | $218.86MM | $206.93MM | $210.64MM |
Operating Cash Flow | $-78.24MM | $-62.59MM | $-75.81MM |
Capital expenditure | $12.31MM | $0.13MM | $0.05MM |
Investing Cash Flow | $87.52MM | $-73.40MM | $13.73MM |
Financing Cash Flow | $65.10MM | $56.78MM | $86.11MM |
Earnings Per Share* | $-2.33 | $-1.81 | $-1.66 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.